[Intrauterine contraception: CNGOF Contraception Guidelines].

{"article_title":"[Intrauterine contraception: CNGOF Contraception Guidelines].","author":"Vidal F, Paret L, Linet T, Tanguy le Gac Y, Guerby P","journal_title":"Gynecologie, obstetrique, fertilite & senologie","issn":"2468-7189","isbn":"","publication_date":"2018-12-01","volume":"46","issue":"12","first_page":"806","page_count":"","accession_number":"30429071","doi":"10.1016\/j.gofs.2018.10.004","publisher":"Elsevier Masson SAS","doctype":"Journal Article","subjects":"France; Contraception methods; Intrauterine Devices adverse effects; Adolescent; Adult; Device Removal; Female; France; Humans; Pelvic Inflammatory Disease; Pregnancy; Pregnancy, Ectopic; Sexually Transmitted Diseases diagnosis; Sexually Transmitted Diseases drug therapy; Uterine Hemorrhage","interest_area":["Obstetrics & Gynecology"],"abstract":"Objective: To provide national clinical guidelines focusing on intrauterine contraception. Methods: A systematic review of available literature was performed using Pubmed and Cochrane libraries. American, British and Canadian guidelines were considered as well. Results: Intrauterine contraception (IUC) displays a wide panel of indications, including adolescents, nulliparous, patients living with HIV before AIDS (Grade B) and women with history of ectopic pregnancy (Grade C). Cervical cancer screening should not be modified in women with IUC (Grade B). Bimanual examination and cervix inspection are mandatory before device insertion (Grade B). Patients should not systematically undergo screening for sexually transmitted infections (STI) before device insertion (Grade B). Screening for STI should be preferably done before insertion but it can be performed at the time of device insertion in asymptomatic women (Grade B). Routine antibiotic prophylaxis and premedication are not recommended before insertion (Grade A). A follow-up visit may be offered several weeks after insertion (Professional consensus). Routine pelvic ultrasound examination in not recommended after device insertion (Grade B). In patients with IUC, unscheduled bleeding, when persistent or associated with pelvic pain, requires further investigation to rule out complication (Professional agreement). Suspected uterine perforation warrants radiological workup to locate the device (Professional consensus). Laparoscopic approach should be preferred for elective removal of intrauterine device from abdominal cavity (Professional consensus). In case of accidental pregnancy with intrauterine device in situ, ectopic pregnancy should be excluded (Grade B). In case of viable and desired intrauterine pregnancy, intrauterine device removal is recommended if the strings are reachable (Grade C). Detection of Actinomyces-like organisms on pap smear in asymptomatic patients with intrauterine contraception does not require further intervention (Grade B). Immediate removal of intrauterine device is not recommended in case of STI or pelvic inflammatory disease (Grade B). Device removal should be considered in the absence of clinical improvement after 48 to 72 hours of appropriate treatment (Grade B). Conclusion: Intrauterine contraception is a long-acting and reversible contraception method displaying great efficacy and high continuation rate. In contrast, complication rate is low. It should thus be offered to both nulliparous and multiparous women. Copyright \u00a9 2018. Published by Elsevier Masson SAS.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=30429071","isPdfLink":false,"isSAML":false,"an":"30429071","number_other":"","type_pub":"","issn_electronic":"2468-7189","languages":"French","language":"fre","date_entry":"Date Created: 20181116 Date Completed: 20190416 Latest Revision: 20190416","date_update":"20240105","titleSource":"Gynecologie, obstetrique, fertilite & senologie [Gynecol Obstet Fertil Senol] 2018 Dec; Vol. 46 (12), pp. 806-822. Date of Electronic Publication: 2018 Nov 11.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2018-12-01","description":"Objective: To provide national clinical guidelines focusing on intrauterine contraception.<br \/>Methods: A systematic review of available literature was performed using Pubmed and Cochrane libraries. American, British and Canadian guidelines were considered as well.<br \/>Results: Intrauterine contraception (IUC) displays a wide panel of indications, including adolescents, nulliparous, patients living with HIV before AIDS (Grade B) and women with history of ectopic pregnancy (Grade C). Cervical cancer screening should not be modified in women with IUC (Grade B). Bimanual examination and cervix inspection are mandatory before device insertion (Grade B). Patients should not systematically undergo screening for sexually transmitted infections (STI) before device insertion (Grade B). Screening for STI should be preferably done before insertion but it can be performed at the time of device insertion in asymptomatic women (Grade B). Routine antibiotic prophylaxis and premedication are not recommended before insertion (Grade A). A follow-up visit may be offered several weeks after insertion (Professional consensus). Routine pelvic ultrasound examination in not recommended after device insertion (Grade B). In patients with IUC, unscheduled bleeding, when persistent or associated with pelvic pain, requires further investigation to rule out complication (Professional agreement). Suspected uterine perforation warrants radiological workup to locate the device (Professional consensus). Laparoscopic approach should be preferred for elective removal of intrauterine device from abdominal cavity (Professional consensus). In case of accidental pregnancy with intrauterine device in situ, ectopic pregnancy should be excluded (Grade B). In case of viable and desired intrauterine pregnancy, intrauterine device removal is recommended if the strings are reachable (Grade C). Detection of Actinomyces-like organisms on pap smear in asymptomatic patients with intrauterine contraception does not require further intervention (Grade B). Immediate removal of intrauterine device is not recommended in case of STI or pelvic inflammatory disease (Grade B). Device removal should be considered in the absence of clinical improvement after 48 to 72 hours of appropriate treatment (Grade B).<br \/>Conclusion: Intrauterine contraception is a long-acting and reversible contraception method displaying great efficacy and high continuation rate. In contrast, complication rate is low. It should thus be offered to both nulliparous and multiparous women.<br \/> (Copyright © 2018. Published by Elsevier Masson SAS.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=30429071&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Vidal F, Paret L, Linet T, Tanguy le Gac Y, Guerby P"}